ABSTRACT: Stress, commonly associated with weaning, marketing, and shipment of feeder cattle, can compromise immune function, and vaccine administration during immunosuppression may reduce vaccine efficacy and calf growth. Four treatments were compared in a 2 × 2 factorial arrangement to evaluate the effect of on-arrival (d 0) vs. delayed (d 14) administration of clostridial (CLOS) and respiratory (RESP) vaccines on health, performance, bovine viral diarrhea virus (BVDV) antibody titers, and physiological immune measurements of high-risk, newly received calves. Crossbred bull and steer calves (n = 263) were weighed (239 ± 1.2 kg), stratified by sex, and randomly assigned to vaccination treatment: 1) arrival CLOS, arrival RESP (ACAR); 2) arrival CLOS, delayed RESP (ACDR); 3) delayed CLOS, arrival RESP (DCAR); and 4) delayed CLOS, delayed RESP (DCDR). Body weight and blood samples were collected on d 0, 14, 28, 42, and 56. Average daily gain did not differ (P ≥ 0.34), averaging 0.98, 0.93, 0.95, and 0.91 kg/d for ACAR, ACDR, DCAR, and DCDR, respectively, for the entire 56-d trial. Vaccination timing did not affect morbidity (P ≥ 0.23); however, there tended to be a CLOS timing effect (P = 0.07) and RESP timing effect (P = 0.09) on days to initial bovine respiratory disease (BRD) treatment. Average days to initial BRD treatment were less for ACAR (6 ± 0.8 d) compared with DCDR (8 ± 0.8 d; P = 0.01). Greater white blood cell counts were observed for DCDR than ACDR (P = 0.01), with ACAR and DCAR being intermediate. Serum cortisol concentrations were greater on d 0 than d 14 (P < 0.01) or d 28 (P = 0.01) but no treatment × day interaction (P = 0.21) was observed. Timing of RESP administration affected (P = 0.001) serum BVDV type I titers, with greater (P < 0.01) levels in calves receiving RESP vaccine on arrival. Delaying CLOS or RESP vaccination did not affect BW gain or morbidity in high risk, newly received stocker calves. Calves administered RESP vaccine on d 0 developed antibody titers to BVDV type I earlier than delayed RESP treatments. Total white blood cell count was greatest when RESP and CLOS vaccination were delayed (DCDR).
INTRODUCTION
Bovine respiratory disease (BRD) is the leading cause of morbidity and mortality according to a recent survey of US feedlots (Woolums et al., 2005) , resulting in significant economic losses to the beef cattle industry. Calves purchased at local auction markets throughout the southeastern United States are typically classified as high-risk for developing signs of BRD because these cattle are of unknown origin and recently weaned from small cow-calf operations that seldom utilize vaccination or other BRD prevention strategies (NAHMS, 1997) .
These high-risk cattle may be suffering stress effects resulting from a combination of commingling, transport, nutritional, weaning, and environmental stressors that can compromise the immune system (Smith, 2004) , and the transportation stress period can endure for as long as 15 d postarrival based on serum hemolytic complement concentration (Purdy et al., 2000) . Vaccination against viral pathogens, bacterial pathogens, or both that contribute to BRD can be an effective preventative strategy; however, vaccine efficacy may be reduced if administered during a period of immunosuppression (Callan, 2001) . A review of field vaccine efficacy by Perino and Hunsaker (1997) suggested that administering BRD vaccination at arrival in North American feedlots was generally not supported by published research. Other complications with on-arrival vaccination may include reduced BW gain performance (Chirase et al., 2001; Richeson et al., 2008) , perhaps due to immunological challenge from vaccine antigens during a period when calves may be experiencing stress-induced immunosuppression. Thus, our objective was to evaluate the effect of delaying respiratory and clostridial vaccination (d 14 vs. arrival) on health, performance, serum bovine viral diarrhea virus (BVDV) type I titers, and physiological stress and immune measures in high-risk, newly received calves.
MATERIALS AND METHODS
Animal methods were approved by the University of Arkansas Animal Care and Use Committee.
Crossbred bull (n = 207) and steer (n = 57) calves (BW = 239 ± 1.2 kg) were procured by an order buyer from multiple auction markets located in western Arkansas and eastern Oklahoma and shipped to the University of Arkansas Agricultural Experiment Station located near Savoy. These calves were likely commingled extensively from numerous herds and were experiencing other stressors described by Smith (2004) and thus would be considered high-risk for BRD. Three separate shipment dates representing each block in the experimental model were received on February 12 (block 1, n = 90), March 1 (block 2, n = 91), and April 17, 2007 (block 3, n = 83). Calves in each block were divided into 8 pens (10 to 12 calves/pen); thus, each of the 4 treatments was replicated 6 times.
Upon arrival, cattle within each block were weighed, assigned a unique ear identification tag, and sorted according to sex (bull or steer). Within sex, calves were randomly distributed to 1 of 8 pens. The 8 pens had been randomly assigned to 1 of 4 vaccination-timing treatments (Table 1) . Treatments were arranged as a 2 × 2 factorial with Clostridium chauvoei, septicum, novyi, and sordellii and perfringens types C & D bacterin-toxoid in a special oil adjuvant (Alpha 7, Boehringer Ingelheim Vetmedica, St. Joseph, MO; CLOS) and infectious bovine rhinotracheitis, BVDV type 1a (Singer strain) and type 2a (Bolin 296 strain), parainfluenza 3, and bovine respirtatory syncytial virus modified-live virus vaccine (Express 5, Boehringer Ingelheim Vetmedica; RESP) administered on arrival (d 0) or delayed (d 14) . This resulted in the 4 treatments: 1) arrival CLOS and RESP (ACAR), 2) arrival CLOS and delayed RESP (ACDR), 3) delayed CLOS, and arrival RESP (DCAR), and 4) delayed CLOS and RESP (DCDR). Treatments were not arranged spatially according to vaccination treatment; because of random treatment assignment, there were instances where vaccinated and nonvaccinated calves had fence-line contact during the study. However, using the same RESP vaccine as in the current study, Kleiboeker et al. (2003) concluded that shedding of BVDV type I or II in calves after vaccination was nonexistent or undetected and did not result in transmission of either BVDV genotype in pregnant contact control cows.
In addition to receiving their assigned vaccination treatment on d 0, calves were treated for internal and external parasites (Cydectin, Fort Dodge Animal Health, Fort Dodge, IA), branded, administered metaphylactic antibiotic treatment with tilmicosin (Micotil, Elanco Animal Health, Indianapolis, IN) according to BW, and bull calves were surgically castrated. An ear notch sample was collected from each animal to test for persistently infected BVDV (Cattle Stats, Oklahoma City, OK). One animal in block 1 was identified as such and was removed from the study pen and quarantined Richeson et al. on d 3. Furthermore on d 0, blood samples from 5 randomly selected animals in each pen were collected from a jugular vein into untreated vacuum tubes (10 mL, Vacutainer, BD Inc., Franklin Lakes, NJ) for subsequent analysis of serum cortisol concentrations and BVDV type I titer levels (plain tube). A second blood sample (10 mL) was collected into vacuum tubes containing EDTA (BD Inc.) for determination of white blood cell (WBC) total and differential counts. Cattle were then moved to their assigned 0.45-ha pens and provided 0.9 kg/calf (as-fed basis) of a receiving supplement (20.6% CP, DM basis; Table 2 ) and free-choice access to bermudagrass hay (14.5% CP, 33.6% ADF, 68.3% NDF, and 7.9% ash, DM basis). Supplement was offered daily at 0800 h and increased to a maximum of 1.8 kg/calf daily as calves began consuming the supplement.
A booster vaccination of RESP was administered 14 d after initial RESP vaccination according to treatment protocol (Table 1) . Cattle were re-weighed, unshrunk, before offering supplement at 14-d intervals during the trial (d 14, 28, 42, and 56) to determine interim and overall differences in BW gain performance. The same 5 animals per pen selected for blood collection upon arrival were similarly sampled on d 14, 28, 42, and 56.
Blood in the plain tubes was centrifuged at 2,100 × g for 20 min at 20°C, and serum was stored frozen at −20°C until analyzed. Serum cortisol concentrations were used as an indication of overall physiological stress and were determined using commercially available RIA kits (Coat-A-Count, DPC, Los Angeles, CA) with an intra-and interassay CV of 1.04 and 23.0%, respectively. Sensitivity of the assay was 0.2 µg/100 mL. The use of this assay in cattle has been previously validated (Godfrey et al., 1991) . Frozen serum samples were shipped on ice via overnight parcel service to the Oklahoma Animal Disease Diagnostic Laboratory (Stillwater) for determination of serum neutralizing antibodies for BVDV type I. Whole blood collected in tubes containing EDTA was kept refrigerated and used within 24 h to determine concentrations (n cells/µL) of total WBC, concentrations and percentages of differential WBC (lymphocytes, neutrophils, monocytes, eosinophils, and basophils), total red blood cells, hemoglobin, hematocrit, and platelets with an automated hematology analyzer (Cell-Dyn 3500 system, Abbott Laboratories, Abbot Park, IL) standardized for analysis of bovine blood.
After arrival metaphylaxis with tilmicosin (Micotil, Elanco Animal Health, Indianapolis, IN), a 48-h posttreatment interval was implemented; therefore, calves were observed each morning beginning on d 3 of the study for clinical signs of respiratory illness by 2 experiment station personnel having a combined 20-yr experience evaluating cattle with BRD. These personnel were present during processing and were not blinded to treatment; however, no records left at the facility identified treatment assignments. Signs used to identify respiratory illness included depression, nasal and ocular discharge, cough, increased respiratory rate, and poor appetite. Cattle with 2 or more visual signs of BRD were removed from their pen and considered morbid if rectal temperature was ≥40°C. Morbid animals were given antibiotic therapy according to a predetermined antibiotic treatment protocol and returned to the home pen. A re-check temperature was taken 48 h after initial treatment with florfenicol (Nuflor, Schering-Plough Animal Health, Summit, NJ). If the recheck temperature was ≥40°C, a second antibiotic treatment with ceftiofur crystalline free acid (Excede, Pfizer Animal Health, New York, NY) was administered. A 72-h posttreatment interval was implemented for cattle administered ceftiofur crystalline free acid, and rectal temperature was re-evaluated. If the recheck temperature was ≥40°C, a third and final antibiotic treatment with danofloxacin mesylate (A180, Pfizer Animal Health) was administered and repeated 48 h after the first injection. Cattle that continued to display BRD symptoms after the third treatment were considered chronically ill, and no further antibiotic treatment was administered. If at any time a re-check temperature was <40°C, the animal was left untreated unless further symptoms developed. Treatment data recorded for individual animal included treatment date, rectal temperature, and the amount and type of antibiotic administered.
Titers were evaluated to determine differences in the concentration of BVDV type I antibodies and the percentage of animals in each treatment with positive seroconversion to BVDV type I using the serum neutralization method as described by Rosenbaum et al. (1970) . Titers were reported as the reciprocal of the greatest dilution of serum to provide complete protection of cells. The least dilution of serum tested was 1:4, whereas the greatest dilution tested was 1:256. Serum that did not provide protection at the 1:4 level was reported as <4 and was considered negative for seroconversion to BVDV. Samples with a reported serum neutralization value of ≥4 were considered positive for 
Statistical Analysis
Performance and morbidity data were analyzed as a randomized complete block design using the PROC MIXED procedure (SAS Inst., Inc., Cary, NC). Pen was considered the experimental unit. The class statement included block (date of arrival), treatment, and replicate. Block and block × replicate × treatment were treated as random effects in the model. Single degree of freedom orthogonal contrasts evaluating effects of CLOS timing, RESP timing, and the interaction were used. If the interaction was significant (P ≤ 0.10), treatment means were separated with a t-test using the PDIFF option in SAS. Cortisol, total and differential WBC, total red blood cell, hemoglobin, hematocrit, platelets, and BVDV type I titer data were analyzed using the PROC MIXED procedure with repeated measures. Pen was considered the experimental unit for these data. The model included treatment, day and treatment × day. Block, replicate, treatment, and day were used in the class statement. Block was the random variable, and the repeated statement was day with block × treatment within replicate as the subject. The covariance model structure used was AR(1). Contrasts for the repeated measures data included CLOS timing, RESP timing, their interaction, and linear, quadratic, cubic, and for some variables quartic effects of day.
RESULTS AND DISCUSSION

Performance
No differences (P ≥ 0.34) in ADG were observed during the 56-d receiving period (Table 3) . Experiments involving vaccination timing of newly received calves are conflicting. In one trial (Richeson et al., 2008) , calves that received delayed (14 d) vaccination of a modifiedlive virus (MLV) respiratory vaccine (Express 5) had greater ADG. Kreikemeier et al. (1996) observed that during the initial 21 d of the feedlot receiving period, calves vaccinated for BRD with a killed-virus at the farm before weaning and revaccinated with a killed virus at the time of commingling at a salebarn tended to gain BW faster than calves given a MLV upon arrival at the feedyard and revaccinated 21 d after feedyard arrival. Conversely, Duff et al. (2000) reported no differences in BW gain among 4 vaccination treatments, including 1) no vaccine (control); 2) delayed 4-way [infectious bovine rhinotracheitis, BVDV, parainfluenza 3 , bovine respiratory syncytical virus] MLV vaccination until d 7; 3) intranasal infectious bovine rhinotracheitisparainfluenza 3 administered on d 0 with delayed 4-way MLV vaccination until d 7; and 4) 4-way MLV vaccination on both d 0 and 7. Clostridial vaccines contain a special and often proprietary adjuvant used to enhance the immune response to the killed antigens contained in the vaccine; however, the effect of different adjuvants on animal performance deserves consideration. Chirase et al. (2001) conducted 2 experiments to evaluate the effects of clostridial vaccines and injection site on performance. In Exp. 1, calves given an injection of saline subcutaneously prescapula (control) had greater (P < 0.01) ADG than calves injected subcutaneously prescapula with Vision 7 (7-way clostridial, Intervet Inc., Millsboro, DE) or Ultra 7 (7-way clostridial, Pfizer Animal Health) but not Alpha 7 injected subcutaneously prescapula or in the ear, which is the clostridial vaccine used in the current study. Spurlock (1997) reported that repeated immune stimulation can result in decreased growth of an animal because nutrients are preferentially utilized for immune and homeostatic pathways. Conflicting results of vaccination on receiving cattle performance may be due to several host factors such as vitamin/mineral status, vaccination history, and the stress level of a particular group. Further research is needed to evaluate the effects of vaccination on animal performance during the receiving period.
Health
The majority of the cattle became sick with 69% of all calves being treated at least one time for BRD (Table 4), but morbidity rates were not different among treatments (P > 0.23). Likewise, no differences were observed in the number of 2nd (P ≥ 0.18) or 3rd (P ≥ 0.37) BRD treatments. Combined death loss (1.9%) did not differ (P ≥ 0.64) among treatments. There was a vaccine type × timing interaction (P = 0.05) for the percentage of chronic animals; ACDR had a greater percentage of chronic animals than ACAR (P = 0.04) and DCDR (P = 0.08), but not DCAR (P = 0.26).
There was a tendency for CLOS (P = 0.07) and RESP (P = 0.09) timing effects on days to initial BRD treatment. Days to initial BRD treatment were fewer (P = 0.01) for ACAR (6 ± 0.76 d) than DCDR (8 ± 0.76 d). This difference may be a result of additive effects of on-arrival vaccination on the visual symptoms of BRD in cattle receiving CLOS and RESP on d 0 (ACAR) vs. cattle receiving no vaccine until d 14 (DCDR). The increase of early visual BRD symptoms in cattle receiving vaccination on arrival did not translate to increased (P ≥ 0.23) morbidity rates. However, there was a numerical difference; 73.4% of cattle receiving RESP on-arrival required treatment for BRD compared with 65.1% of cattle that received delayed RESP vaccina-tion. Furthermore, CLOS (P = 0.01) and RESP (P = 0.05) timing affected rectal temperature at the time of initial antibiotic treatment. Delaying either vaccine resulted in a greater rectal temperature at the time of initial antibiotic treatment. Because DCDR calves were removed from their pens later than the other treatments, discrepancy in disease stage may explain the greater rectal temperature at the time of initial BRD treatment. There was also an impact (vaccine type × timing interaction, P = 0.05) on the days to treatment with the second antibiotic; DCDR calves were treated later (d 13 ± 1.3) than calves on the other treatments (d 9 ± 1.3).
BVDV Type I Antibody Titers
Two separate comparison methods were used to evaluate differences in BVDV type I titers: 1) trialday basis and 2) equivalent-day post-RESP vaccination basis. Furthermore, results were analyzed and reported as antibody concentration or percentage positive seroconversion as described previously in the Materials and Methods.
Trial-Day Basis Comparison. As anticipated there was a treatment × day interaction (P ≤ 0.04) for BVDV type I titers for both analyses. On d 14, BVDV type I titer levels for ACAR were greater than ACDR (P = 0.001) or DCDR (P = 0.01, Figure 1 ). On d 28, both treatments administered RESP on-arrival (ACAR and DCAR) had greater (P ≤ 0.005) BVDV type I titers than treatments administered delayed RESP vaccination (ACDR and DCDR). No treatment differences (P ≥ 0.10) existed on d 42. Results were similar when trial-day basis titer data were analyzed as percentage seroconversion to BVDV type I (Figure 2 ). Positive seroconversion to BVDV type I was faster (P = 0.01) Means within a row without a common superscript are different (P < 0.05). Equivalent-Day, Post-RESP Comparison. There was no treatment × day interaction (P ≥ 0.82) for the equivalent-day post-RESP comparison method. The overall log 2 concentration of BVDV type I antibody was 5.2, 4.9, 5.0, and 4.7 for ACAR, ACDR, DCAR, and DCDR treatments, respectively, but not different (P = 0.68). Likewise, no differences (P = 0.56) were detected when analyzed as percentage seroconversion by the equivalent-day post-RESP comparison.
The BVDV titer results in this study suggest that high-risk, newly received calves administered RESP vaccination on-arrival are able to respond adequately to RESP vaccination despite the typical stress and immune challenges present during the initial 14 d of receiving. Natural disease exposure and subsequent host immune response may have affected BVDV type I antibody titers; however, the extent to which this may have occurred is unknown. Measurement of BVDV neutralizing antibody titers has been reported to provide an indication of the amount of BVDV protection present in calves (Bolin and Ridpath, 1995) and has been positively correlated with disease prevention (Howard et al., 1989) . Although calves administered RESP on arrival developed titers to BVDV type I faster, there was not a decrease (P ≥ 0.23) in morbidity or increase in protection as was reported in other studies (Howard et al., 1989; Bolin and Ridpath, 1995) . However, Howard et al. (1989) and Bolin and Ridpath (1995) were both BVDV challenge studies where calves were only exposed to BVDV, whereas in our study the specific agent causing morbidity was not tested and therefore unknown. In the current study it is likely that more than 1 viral or bacterial pathogen, or both, was causing morbidity, which may or may not have been vaccinated against.
Total and Differential WBC Count
There was no treatment × day interaction for total WBC count (P = 0.97). There tended to be a main effect of CLOS timing (P = 0.08) on total WBC count (Table 5) . Overall, delaying CLOS resulted in greater WBC counts. There was also a vaccine type × timing interaction (P = 0.06); DCDR had greater WBC counts than ACDR (P = 0.01), and ACAR and DCAR were intermediate. The greater WBC counts recorded for DCDR may indicate that these cattle had greater occurrence of pathogenic infection. However, greater total WBC count may also indicate that an animal has increased ability to mount an innate or adaptive immune response to a foreign antigen, which is a key goal of vaccination. There were effects of day of sampling on differential percentages (Figure 3 ), concentrations (data not shown), and total WBC count (Figure 4) . The percentage of lymphocytes (quartic, P < 0.001), monocytes (quartic, P = 0.02), eosinophils (linear, P < 0.001), and the WBC count (quartic, P < 0.001) increased as the study progressed, whereas the per- centage of neutrophils decreased (quartic, P < 0.001) over time. Concentrations of differential WBC reacted similarly with number of neutrophils decreasing (quadratic, P < 0.001) and numbers of lymphocytes (quadratic, P < 0.001), monocytes (quadratic, P = 0.001), eosinophils (linear, P < 0.001), and basophils (linear, P < 0.001) increasing as the study progressed. Previous studies measuring total leukocytes before and after transport observed different results. Blecha et al. (1984) reported greater total leukocyte concentration at unloading and 7 d after receiving in transported steers vs. nontransported controls. In contrast to our results, Stanger et al. (2005) observed a transient decrease in total leukocyte count when measured 48 h before, 72 h after, and 216 h after transport of Bos indicus steers. The neutrophil:lymphocyte ratio (N:L), reported as an indicator of shipping stress in pigs (McGlone et al., 1993) and social stress in chickens (Gross and Siegel, 1983) , was also affected by day of sampling (quartic, P ≤ 0.05). As the study progressed, the N:L decreased; therefore, physiological stress early in the receiving period seemingly elevated the N:L ratio of calves across all treatments.
There were no treatment × day interactions (P ≥ 0.18) for differential percentages or concentrations of WBC. Overall, CLOS timing affected some differential percentages and concentrations. Delaying CLOS increased (P ≤ 0.02) the percentage and concentration of lymphocytes and decreased (P ≤ 0.05) the percentage of monocytes, and the percentage and concentration of eosinophils. The N:L tended to be affected by a vaccine type × timing (P = 0.10) interaction; DCDR had the smallest N:L. Therefore, postponing both vaccines 14 d may have reduced stress.
Red blood cells and platelets were greatest (P = 0.02) in calves administered delayed RESP vaccination (Fig- Means within a row without a common superscript are different (P ≤ 0.05). Effect of day on differential proportions of white blood cells. Basophils: cubic effect of day (P = 0.04). Eosinophils: linear effect of day (P < 0.001). Monocytes: linear (P < 0.001) and quartic (P = 0.02) effects of day. Lymphocytes: linear, quadratic, cubic, and quartic effects of day (P < 0.001). Neutrophils: linear, quadratic, cubic, and quartic effects of day (P < 0.001). ure 4). Red blood cells (quadratic, cubic, and quartic effects of day, P ≤ 0.05), hemoglobin (linear, quadratic, cubic, and quartic effects of day, P ≤ 0.05), and hematocrit (quadratic and cubic effects of day, P < 0.001) were least on d 14. Platelet concentrations were the least on d 56 (quadratic, P = 0.01).
Serum Cortisol
There was no treatment × day interaction (P = 0.21) for serum cortisol concentrations (Figure 5 ), nor were there any treatment differences (P ≥ 0.53); however, there was a significant day effect (P = 0.002) on cortisol concentrations. Cortisol concentrations averaged 3.04 µg/100 mL on d 0 and declined on d 14 (2.43 µg/100 mL, P < 0.001) and d 28 (2.57 µg/100 mL, P = 0.01), suggesting that physiological stress was greatest during the first 14 d of the receiving period. Several studies report stress induced increases in cortisol concentrations (Kegley et al., 1997; Tyler and Cummins, 2003; Gupta et al., 2005) , and Anglen et al. (2003) observed animals that underwent restraint stress failed to mount a normal immune response, which resulted in increased susceptibility to a subsequent pathogen challenge. Crookshank et al. (1979) reported that corticosteroids were most responsive to transport stress; however, other trials reported no differences in cortisol related to weaning (Lefcourt and Elsasser, 1995) or transport (Galyean et al., 1981) stress. According to results of the current study, the early physiological stress during re- Figure 4 . Effect of day on cellular blood constituents. White blood cells: linear (P < 0.001), quadratic (P = 0.03), and quartic (P = 0.01) effects of day. Neutrophil:lymphocyte and hemoglobin: linear, quadratic, cubic, and quartic effects of day (P ≤ 0.05). Red blood cells: quadratic, cubic, and quartic effects of day (P ≤ 0.05). Hematocrit: quadratic and cubic effects of day (P < 0.001). Platelets: quadratic effect of day (P = 0.01).
ceiving indicated by serum cortisol concentrations, did not affect the ability to respond to vaccination because calves administered RESP on-arrival (ACAR, DCAR) had adequate and earlier titer response to BVDV type I compared with the delayed RESP treatments (ACDR, DCDR). Likewise, Blecha et al. (1984) reported that increased cortisol did not correlate with a suppressed immune response.
In conclusion, timing of vaccination did not affect ADG or health in high-risk, newly received calves. Antibody titers to BVDV type I developed earlier when cattle were administered a respiratory vaccine on d 0 vs. 14. Several differential WBC measures were greater when both clostridial and respiratory vaccines were delayed. This observation may correlate to the occurrence of pathogenic infection or differences in immune status. Serum cortisol concentation was greatest during the first 14 d of receiving; however, cortisol concentration did not affect BVDV type I titer response and vaccination timing did not affect cortisol level. 
